Dasiglucagon Effectively Reduces Postprandial Hypoglycemia A
In a randomized, double-blind, placebo-controlled, crossover trial, 10 RYGB-operated participants with continuous glucose monitoring–verified PBH were randomly assigned to 3 trial days, each consisting of a 240-min standardized liquid mixed-meal test with the subcutaneous injection of placebo or 80 g or 200 g dasiglucagon.

Compared with placebo, treatment with both 80 and 200 µg dasiglucagon raised nadir plasma glucose (PG) (placebo: 3.0 ± 0.2 mmol/L [mean ± SEM]; 80 g dasiglucagon: 3.9 ± 0.3 mmol/L, P = 0.002; 200 g dasiglucagon: 4.5 ± 0.2 mmol/L, P = 0.0002) and reduced time in hypoglycemia (PG <3.9 mmol/L) by 70.0 min (P = 0.030 and P = 0.008).

Single-dose administration of dasiglucagon effectively mitigated postprandial hypoglycemia.

Source: https://diabetesjournals.org/care/article-abstract/doi/10.2337/dc21-2252/144881/Dasiglucagon-Effectively-Mitigates-Postbariatric?redirectedFrom=fulltext
Like
Comment
Share